Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,390,000 shares, a growth of 29.9% from the March 15th total of 1,070,000 shares. Approximately 6.5% of the shares of the company are sold short. Based on an average daily volume of 141,400 shares, the days-to-cover ratio is currently 9.8 days.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Citigroup Inc. acquired a new position in Dianthus Therapeutics during the third quarter worth $53,000. FMR LLC acquired a new position in Dianthus Therapeutics during the third quarter worth $28,961,000. Acadian Asset Management LLC acquired a new position in Dianthus Therapeutics during the third quarter worth $303,000. Atlas Venture Life Science Advisors LLC acquired a new position in Dianthus Therapeutics during the third quarter worth $3,240,000. Finally, Avidity Partners Management LP acquired a new position in Dianthus Therapeutics during the third quarter worth $16,644,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DNTH shares. Jefferies Financial Group lifted their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 22nd. Stifel Nicolaus started coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a "buy" rating and a $44.00 target price on the stock. Finally, Wedbush lifted their target price on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an "outperform" rating in a research note on Friday, March 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $37.00.

Dianthus Therapeutics Stock Down 2.4 %

Shares of DNTH traded down $0.62 during mid-day trading on Monday, hitting $25.27. The company's stock had a trading volume of 197,131 shares, compared to its average volume of 141,293. The firm has a 50-day simple moving average of $25.72 and a 200 day simple moving average of $16.91. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.73 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -1.92 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.